StreetInsider.com News Articles

ABL Diagnostics - Proposed Transfer of the Listing of Its Securities From the Regulated Market of Euronext Paris to Euronext Growth Paris

Fri, 07 Aug 2026 12:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

ABL Diagnostics (Euronext Paris: ABLD – ISIN: FR001400AHX6) (the "Company"), an international company specializing in innovative molecular biology tests and global solutions for laboratories, announces that its Board of Directors, meeting on August 6, 2026, has decided to convene a shareholders' meeting on September 17, 2026, for the purpose of submitting for their approval the proposed transfer of the listing of the Company's securities from the regulated market of Euronext Paris to the Euronext Growth Paris multilateral trading facility.

Rationale for the proposed transfer

This proposed transfer would allow the Company to be listed on

ABL Diagnostics - Proposed Transfer of the Listing of Its Securities From the Regulated Market of Euronext Paris to Euronext Growth Paris

Fri, 07 Aug 2026 12:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

Rationale for the proposed transfer

This proposed transfer would allow the Company to be listed on

ABL Diagnostics - Proposed Transfer of the Listing of Its Securities From the Regulated Market of Euronext Paris to Euronext Growth Paris

Fri, 07 Aug 2026 12:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

Rationale for the proposed transfer

This proposed transfer would allow the Company to be listed on

ABL Diagnostics - Proposed Transfer of the Listing of Its Securities From the Regulated Market of Euronext Paris to Euronext Growth Paris

Fri, 07 Aug 2026 12:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

Rationale for the proposed transfer

This proposed transfer would allow the Company to be listed on

ABL Diagnostics - Proposed Transfer of the Listing of Its Securities From the Regulated Market of Euronext Paris to Euronext Growth Paris

Fri, 07 Aug 2026 12:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

Rationale for the proposed transfer

This proposed transfer would allow the Company to be listed on

ABL Diagnostics - Proposed Transfer of the Listing of Its Securities From the Regulated Market of Euronext Paris to Euronext Growth Paris

Fri, 07 Aug 2026 12:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

Rationale for the proposed transfer

This proposed transfer would allow the Company to be listed on

ABL Diagnostics - Proposed Transfer of the Listing of Its Securities From the Regulated Market of Euronext Paris to Euronext Growth Paris

Fri, 07 Aug 2026 12:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

Rationale for the proposed transfer

This proposed transfer would allow the Company to be listed on

ABL Diagnostics - Proposed Transfer of the Listing of Its Securities From the Regulated Market of Euronext Paris to Euronext Growth Paris

Fri, 07 Aug 2026 12:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

Rationale for the proposed transfer

This proposed transfer would allow the Company to be listed on

ABL Diagnostics - Proposed Transfer of the Listing of Its Securities From the Regulated Market of Euronext Paris to Euronext Growth Paris

Fri, 07 Aug 2026 12:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

Rationale for the proposed transfer

This proposed transfer would allow the Company to be listed on

ABL Diagnostics - Proposed Transfer of the Listing of Its Securities From the Regulated Market of Euronext Paris to Euronext Growth Paris

Fri, 07 Aug 2026 12:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

Rationale for the proposed transfer

This proposed transfer would allow the Company to be listed on

ABL Diagnostics - Proposed Transfer of the Listing of Its Securities From the Regulated Market of Euronext Paris to Euronext Growth Paris

Fri, 07 Aug 2026 12:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

Rationale for the proposed transfer

This proposed transfer would allow the Company to be listed on

ABL Diagnostics - Proposed Transfer of the Listing of Its Securities From the Regulated Market of Euronext Paris to Euronext Growth Paris

Fri, 07 Aug 2026 12:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

Rationale for the proposed transfer

This proposed transfer would allow the Company to be listed on

ABL Diagnostics: Sale of a New Block of Shares by Its Main Shareholder ABL

Wed, 29 Jul 2026 12:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

ABL Diagnostics (Paris:ABLD) announces that its main shareholder, Advanced Biological Laboratories (ABL), a Luxembourg-based diagnostics company, has filed information with the French Financial Markets Authority (AMF) via ONDE, the centralized information filing system, regarding the sale of a new block of ABL Diagnostics shares as part of an over-the-counter transaction with a private third party.

The filing relating to this sale can be viewed in the AMF's database of decisions and financial information (BDIF) at the following address: https://bdif.amf-france.org/fr/details/2026DD1129675.

With the support of its main shareholder, ABL, ABL Diagnostics is continuing

ABL Diagnostics: Sale of a New Block of Shares by Its Main Shareholder ABL

Wed, 29 Jul 2026 12:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

The filing relating to this sale can be viewed in the AMF's database of decisions and financial information (BDIF) at the following address: https://bdif.amf-france.org/fr/details/2026DD1129675.

With the support of its main shareholder, ABL, ABL Diagnostics is continuing

ABL Diagnostics: Sale of a New Block of Shares by Its Main Shareholder ABL

Wed, 29 Jul 2026 12:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

The filing relating to this sale can be viewed in the AMF's database of decisions and financial information (BDIF) at the following address: https://bdif.amf-france.org/fr/details/2026DD1129675.

With the support of its main shareholder, ABL, ABL Diagnostics is continuing

ABL Diagnostics: Sale of a New Block of Shares by Its Main Shareholder ABL

Wed, 29 Jul 2026 12:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

The filing relating to this sale can be viewed in the AMF's database of decisions and financial information (BDIF) at the following address: https://bdif.amf-france.org/fr/details/2026DD1129675.

With the support of its main shareholder, ABL, ABL Diagnostics is continuing

ABL Diagnostics: Sale of a New Block of Shares by Its Main Shareholder ABL

Wed, 29 Jul 2026 12:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

The filing relating to this sale can be viewed in the AMF's database of decisions and financial information (BDIF) at the following address: https://bdif.amf-france.org/fr/details/2026DD1129675.

With the support of its main shareholder, ABL, ABL Diagnostics is continuing

ABL Diagnostics: Sale of a New Block of Shares by Its Main Shareholder ABL

Wed, 29 Jul 2026 12:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

The filing relating to this sale can be viewed in the AMF's database of decisions and financial information (BDIF) at the following address: https://bdif.amf-france.org/fr/details/2026DD1129675.

With the support of its main shareholder, ABL, ABL Diagnostics is continuing

ABL Diagnostics: Sale of a New Block of Shares by Its Main Shareholder ABL

Wed, 29 Jul 2026 12:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

The filing relating to this sale can be viewed in the AMF's database of decisions and financial information (BDIF) at the following address: https://bdif.amf-france.org/fr/details/2026DD1129675.

With the support of its main shareholder, ABL, ABL Diagnostics is continuing

ABL Diagnostics: Sale of a New Block of Shares by Its Main Shareholder ABL

Wed, 29 Jul 2026 12:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

The filing relating to this sale can be viewed in the AMF's database of decisions and financial information (BDIF) at the following address: https://bdif.amf-france.org/fr/details/2026DD1129675.

With the support of its main shareholder, ABL, ABL Diagnostics is continuing

ABL Diagnostics Announces Amendment to the Equity Line and Share Loan Agreement Between Its Main Shareholder ABL SA (Luxembourg) and Alumni Capital

Mon, 27 Jul 2026 12:00:00 -0400

Introduction of a minimum floor price of €4.50 per share for any future drawdown
Reduction of the maximum drawdown size from 50,000 to 2,500 shares
Immediate return of 98,026 loaned shares and permanent termination of any new share lending
Implementation of strict daily and monthly market disposal limitations

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

ABL Diagnostics (Euronext Compartment B – ISIN: FR001400AHX6), a company specialized in vitro diagnostics, announces that on 23 July 2026 an Amended and Restated Equity Line and Share Loan Agreement was executed, amending the initial Equity Line and Share Loan Agreement dated 16 October 2025. The revised agreement

ABL Diagnostics Announces Amendment to the Equity Line and Share Loan Agreement Between Its Main Shareholder ABL SA (Luxembourg) and Alumni Capital

Mon, 27 Jul 2026 12:00:00 -0400

Introduction of a minimum floor price of €4.50 per share for any future drawdown
Reduction of the maximum drawdown size from 50,000 to 2,500 shares
Immediate return of 98,026 loaned shares and permanent termination of any new share lending
Implementation of strict daily and monthly market disposal limitations

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

ABL Diagnostics Announces Amendment to the Equity Line and Share Loan Agreement Between Its Main Shareholder ABL SA (Luxembourg) and Alumni Capital

Mon, 27 Jul 2026 12:00:00 -0400

Introduction of a minimum floor price of €4.50 per share for any future drawdown
Reduction of the maximum drawdown size from 50,000 to 2,500 shares
Immediate return of 98,026 loaned shares and permanent termination of any new share lending
Implementation of strict daily and monthly market disposal limitations

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

ABL Diagnostics Announces Amendment to the Equity Line and Share Loan Agreement Between Its Main Shareholder ABL SA (Luxembourg) and Alumni Capital

Mon, 27 Jul 2026 12:00:00 -0400

Introduction of a minimum floor price of €4.50 per share for any future drawdown
Reduction of the maximum drawdown size from 50,000 to 2,500 shares
Immediate return of 98,026 loaned shares and permanent termination of any new share lending
Implementation of strict daily and monthly market disposal limitations

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

ABL Diagnostics Announces Amendment to the Equity Line and Share Loan Agreement Between Its Main Shareholder ABL SA (Luxembourg) and Alumni Capital

Mon, 27 Jul 2026 12:00:00 -0400

Introduction of a minimum floor price of €4.50 per share for any future drawdown
Reduction of the maximum drawdown size from 50,000 to 2,500 shares
Immediate return of 98,026 loaned shares and permanent termination of any new share lending
Implementation of strict daily and monthly market disposal limitations

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News: